FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US

18,400 resources

Type: Text:

By Version

By Authority

 

Start Prev Rows 10800 - 11000 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.119Enrollment in Hospice Careactive2020-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.120Palliative Careactive2020-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.121Advance Directive Including Durable Power of Attorney or Instructionalactive2020-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.122Carmustine Injectableactive2022-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.123Dacarbazine Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.124Streptozocin Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.126Alemtuzumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.127Azacitidine Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.128Bendamustine Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.129Busulfan Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.130Temozolomide Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.131Thiotepa Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.132Oxaliplatin Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.133Romidepsin Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.134Trabectedin Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.135Dolasetron Oralactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.136Dolasetron Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.137Granisetron Oralactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.138Granisetron Transdermalactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.139Granisetron Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.140Ondansetron Oralactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.141Ondansetron Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.142Ifosfamide Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.143Arsenic Trioxide Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.144Netupitant Palonosetron Oralactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.145Fosnetupitant Palonosetron Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.146Aprepitant Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.147Rolapitant Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.148Dexamethasone Oralactive2022-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.149Dexamethasone Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.150Dexamethasone Drug Implantactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.151Olanzapine Oralactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.152Olanzapine Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.153Idarubicin Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.154Neurokinin 1 Receptor Antagonist Ingredientactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.155Serotonin Receptor Antagonist Ingredientactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.156Clofarabine Injectableactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.157Belinostat Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.158Bortezomib Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.159Cabazitaxel Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.160Carfilzomib Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.161Decitabine Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.162Elotuzumab Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.163Enfortumab Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.164Eribulin Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.165Etoposide Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.166Inotuzumab Ozogamicin Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.167Mitoxantrone Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.168Moxetumomab Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.169Necitumumab Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.170Nelarabine Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.171Temsirolimus Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.172Tisagenlecleucel Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.173Topotecan Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.178Atezolizumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.179Avelumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.180Bleomycin Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.181Cemiplimab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.182Cladribine Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.183Daratumumab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.184Durvalumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.185Emapalumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.186Fludarabine Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.187Ipilimumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.188Nivolumab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.189Pembrolizumab Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.190Polatuzumab Vedotin Injectableactive2021-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.191Pralatrexate Injectableactive2021-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.192Vincristine Injectableactive2021-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.193Methotrexate Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.194Trastuzumab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.195Mitomycin Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.196Brentuximab Vedotin Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.197Doxorubicin Pegylated Liposomal Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.198Blinatumomab Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.199Trastuzumab Emtansine Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.200Gemtuzumab Ozogamicin Injectableactive2021-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.201Tagraxofusp Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.202Axicabtagene Ciloleucel Injectableactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.203BRCA1active2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.204BRCA2active2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.205BRCA1 Testingactive2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.207Epithelial Ovarian Canceractive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.208Primary Peritoneal Canceractive2022-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.209Fallopian Tube Canceractive2022-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.210Multigene Panelactive2023-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.211BRCA1 and BRCA2active2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.212BRCA1 and BRCA2 Testingactive2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.213BRAF V600active2022-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.214BRAF V600 Testingactive2023-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.215Colorectal Canceractive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.216BRAF V600 Mutation Statusactive2022-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.217Cancer Stage Iactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.218Head and Neck Canceractive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.219Malignant Melanoma of Skinactive2022-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.220Brain Canceractive2022-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.221Waldenstrom Macroglobulinemiaactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.222High Emetic Risk Intravenous Antineoplastic Agentactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.223Moderate Emetic Risk Intravenous Antineoplastic Agentactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.224Docetaxel Injectableactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.225Cyclophosphamide Injectableactive2022-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.226LAG 3 Inhibitoractive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.233Chemotherapy Administrationactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.240Pathological N Stage N3cactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.241Audio Visual Telehealth Encounteractive2025-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.242Moderate or High Emetic Risk Oral Antineoplastic Agentactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.243Minimal to Low Emetic Risk Oral Antineoplastic Agentactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.244Copanlisib Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.245Isatuximab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.246Loncastuximab tesirine Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.247Margetuximab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.248Mirvetuximab soravtansine Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.249Tafasitamab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.250Teclistamab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.251Tisotumab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.252Asparaginase Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.254Belantamab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.255Dostarlimab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.256Mosunetuzumab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.257Tremelimumab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.258Indication for Dexamethasoneactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.260Indication for Olanzapineactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.261Indication for Dexamethasoneactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.263Indication for Olanzapineactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.264Prednisoneactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.265As Needed PRNactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.3.266Amivantamab Injectableactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.200Doxorubicinactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.201Epirubicinactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.202Capecitabineactive2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.203Cyclophosphamideactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.204Injectable Fluorouracilactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.205Methotrexateactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.206Trastuzumab and Biosimilarsactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.207HER2 Presence in Tissueactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.208Carboplatinactive2020-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.209Depression Screening for Adultactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.210Long Acting Opioidsactive2020-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.211High Fiber Supplement or Diet Educationactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.212Dexamethasoneactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.213Olanzapineactive2021-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.214Pancreatic Canceractive2020-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.215Audio Visual Telehealth Encounteractive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.216Telephone Encounteractive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.217Telehealth Emergency Department or Initial Inpatientactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.218Dyspnea Assessmentactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.219Nausea or Vomiting Assessmentactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.220Karnofsky Performance Statusactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.221Referral to Hospice Careactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.222Referral to Palliative Careactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.223Palliative Careactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.224Enrollment in Hospice Careactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.225Advance Directive Including Durable Power of Attorney or Instructionalactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.229Minimal Emetic Risk Intravenous Antineoplastic Agentactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.232Epithelial Ovarian Canceractive2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.233Primary Peritoneal Canceractive2022-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.235BRCA2 Testingactive2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.236Multigene Panelactive2023-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.237BRCA1 Testingactive2023-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.238First Line Drug Therapy for Metastatic Colorectal Canceractive2022-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.239BRAF V600 Testingactive2022-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.240Cancer Stage 4active2022-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.241Cancer Stage M1active2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.242High Emetic Risk Intravenous Antineoplastic Agentactive2022-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.243Moderate Emetic Risk Intravenous Antineoplastic Agentactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.245Antiemetic Agentactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.247Indication for Dexamethasoneactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.1444.5.249Indication for Olanzapineactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.2074.1.1.3Race Category Excluding Nullsactive2024-06hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.1002.77Codeineactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.1004.13Dihydrocodeineactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.1004.14Nalbuphineactive2020-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4009Malignant Intracranial Neoplasmactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4010Malignant Intracranial Neoplasmactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4015STEMIactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4016STEMIactive2019-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4017STEMIactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4019Fibrinolytic Therapyactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4023Cerebral Vascular Lesionactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4024Cerebral Vascular Lesionactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4025Cerebral Vascular Lesionactive2019-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4026Closed Head and Facial Traumaactive2019-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4028Aortic Dissection or Ruptured Aortic Aneurysmactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4029Acute Peptic Ulceractive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4030Acute Peptic Ulceractive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4031Acute Peptic Ulceractive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4032Dementia and Related Intracranial Pathologiesactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4033Dementia and Related Intracranial Pathologiesactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4034Active Bleeding or Bleeding Diathesis, Excluding Mensesactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4035Active Bleeding or Bleeding Diathesis, Excluding Mensesactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4036Active Bleeding or Bleeding Diathesis, Excluding Mensesactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4043Dementia and Related Intracranial Pathologiesactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4044Aortic Dissection or Ruptured Aortic Aneurysmactive2022-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4045Oral Anticoagulant Medicationsactive2023-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4046Cardiopulmonary Emergencyactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4047Cardiopulmonary Emergencyactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4048Cardiopulmonary Emergencyactive2022-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4049Mechanical Circulatory Assist Deviceactive2024-07hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4050Mechanical Circulatory Assist Deviceactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113883.3.3157.4052Mechanical Circulatory Assist Deviceactive2025-02hl7